Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
fMRI with sensory stimulation · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| All Participants | EXPERIMENTAL | fMRI studies with sensory stimulation in the presence of 0 mg, 250 mg, 350 mg, and 510 mg cumulative doses of ferumoxytol |
| Name | Type | Description |
|---|---|---|
| fMRI with sensory stimulation | PROCEDURE | BOLD fMRI study with sensory stimulation followed by fMRI in the presence of increasing concentrations of ferumoxytol (Feraheme™) |
Inclusion Criteria: * Participant weighs approximately 55-75 kg and has a Body Mass Index (BMI) of 18-25 kg/m\^2 * Participant is in good health * Participant is a nonsmoker and/or has not used nicotine or nicotine-containing products for at least 6 months Exclusion Criteria: * Participant has a ...
fMRI with sensory stimulation is used for functional magnetic resonance imaging, a technique that measures blood flow in the brain in response to non-drug stimuli. It is an investigational methodology being studied for imaging applications, not a therapeutic treatment.
fMRI with sensory stimulation is being developed by Merck & Company, Inc., traded on the New York Stock Exchange under the ticker MRK. The company conducted a Phase 1 study of this imaging methodology.
fMRI with sensory stimulation is in Phase 1 clinical development. It is an investigational imaging methodology and has not been approved by the FDA. One Phase 1 trial has been completed.
fMRI with sensory stimulation was studied in one completed Phase 1 trial, NCT01244282, titled 'A Study of Two Methodologies for Measuring Blood Flow in the Brain in Response to Non-Drug Stimuli (P08085/MK-0000-180)'. The trial enrolled 10 healthy male volunteers aged 21 years and older.
Yes, fMRI with sensory stimulation is the same as MK-0000-180, as indicated by the trial title 'P08085/MK-0000-180'. The study evaluated two methodologies for measuring brain blood flow in response to non-drug stimuli.